About this trial
The MK5684-01A study is testing a new treatment called Opevesostat (MK-5684), either on its own or in combination with other cancer therapies, for men with metastatic castration-resistant prostate cancer (mCRPC). This form of prostate cancer has spread to other parts of the body and no longer responds to standard hormone therapy. The goal is to understand how Opevesostat works in the body, what side effects it may cause, and whether it helps control the cancer.
This study, part of a larger research project, has two phases. The first is a safety lead-in phase, which will assess how well the treatment is tolerated by the patient and help identify the best dose to use in the next stage. The second phase will explore how effective the treatment is. Participants will receive Opevesostat either alone or with other medicines, attend regular hospital visits, and undergo blood tests and scans. Eligibility includes having mCRPC and meeting certain health and treatment history criteria.
Patient Profile
Metastatic castration-resistant prostate cancer (mCRPC)
Where’s this trial being run?
Cork University Hospital, Tallaght University Hospital, and St Vincents University Hospital
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | MK5684-01A |
|---|---|
| Number: | 24-56 |
| Full Title: | MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) |
| Principal Investigator: | Prof. Ray McDermott (TUH & SVUH), Dr Richard Bambury (CUH) |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | MSD |
| Recruitment Started: |
Global: May 2024 Ireland: Sept 2024 |
| Global Recruitment Target: | 220 |
|---|---|
| Ireland Recruitment Target: | 12 |